Pipeline

Clinical Trials

Secura Bio® is supporting several studies to investigate disease states and/or drug combinations that have not received approval from the FDA or other health authorities. The information presented below does not make any claims with regard to safety or efficacy. There are no guarantees that the outcomes of these studies will result in regulatory approval(s).

Duvelisib
StudyTherapeutic AreaPhaseStatus
PRIMO Single-agent
NCT03372057		Relapsed and / or Refractory Peripheral T-cell Lymphoma2Fully Enrolled
TEMPO Intermittent dosing
NCT03961672		Relapsed and / or Refractory Chronic Lymphocytic
Leukemia		2Enrolling
Duvelisib + nivolumab
NCT03892044		Richter Syndrome or Transformed Follicular Lymphoma2Enrolling
Duvelisib + venetoclax
NCT03534323		Relapsed or Refractory CLL / SLL / RS2Enrolling
Duvelisib + romidepsin or bortezomib
NCT02783625		Peripheral T-cell Lymphoma1Enrolling
Duvelisib intermittent dosing
NCT03961672		CLL / SLL2Enrolling
Duvelisib post-transplant
NCT04331119		Indolent Non-Hodgkin Lymphoma2Enrolling
Duvelisib + nivolumab
NCT04652960		Mycosis Fungoides / Sezary Syndrome1Not Yet Enrolling

Additional areas of interest to the duvalisib development program include new combinations in CLL/SLL and iNHL; DLBCL; T-cell lymphomas; and select solid tumors. Combinations with CAR-Ts, BiTEs, immunotherapies, and other novel mechanisms of action in hematologic and solid malignancies are also under consideration.

For further information contact securabio@tmacmail.com.